Intellia Therapeutics Inc (NTLA NASDAQ) stock market data APIs
$12.3562
-0.22(-1.8%)
as of February 18, 2026
Try our APIs with
free plan!
Intellia Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Prev. Close
12.3562
Open
12.1326
High
12.7387
Low
12.0684
52 wk Range
5.9-28.25
Market Cap
1 446 M
Shares Outstanding
116 M
Revenue
57 528 K
EPS
0
Beta
2.114
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Intellia Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Intellia Therapeutics Inc data using free add-ons & libraries
Get Intellia Therapeutics Inc Fundamental Data
Intellia Therapeutics Inc Fundamental data includes:
- Net Revenue: 57 528 K
- EBITDA: -468 774 016
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-19
- EPS/Forecast: -0.9631
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Intellia Therapeutics Inc News
New
Cathie Wood Buys COIN, HOOD
This article first appeared on GuruFocus. Cathie Wood is clearly sticking to her high conviction themes. Last week, ARK Invest leaned even further into crypto platforms and AI driven healthcare, whil...
Most and least shorted healthcare stocks with up to $2B market cap
Short interest in small-cap healthcare surged toward the end of January, centering heavily on the biotechnology sector. Data as of January 30 shows that KalVista (KALV [https://seekingalpha.com/symbol...
H.C. Wainwright Boosts Intellia (NTLA) Price Target After MAGNITUDE-2 Hold Lifted
Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the best innovative stocks to buy according to Wall Street analysts. H.C. Wainwright reiterated a Buy rating on Intellia Therapeutics, Inc. (NASDA...
Global Gene Therapy and CRISPR Market Shows Billion Dollar Growth with Novartis Zolgensma 1.2 Billion Sarepta Elevidys 611 Million and Emerging CRISPR Collaborations 20 Million
Precedence Research Precedence Research, a leading strategic research firm, today released a comprehensive overview of the gene therapy and CRISPR therapeutics market, highlighting key company perfor...
Get Intellia Therapeutics Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
